Results 51 to 60 of about 19,263 (243)

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

Nature Communications
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu, Lijie Xing, Jiang Li, Kenneth Wen, Ning Liu, Yuntong Liu, Gongwei Wu, Su Wang, Daisuke Ogiya, Tian-Yu Song, Keiji Kurata, Johany Penailillo, Eugenio Morelli, Tingjian Wang, Xiaoning Hong, Annamaria Gulla, Yu-Tzu Tai, Nikhil Munshi, Paul Richardson, Ruben Carrasco, Teru Hideshima, Kenneth C. Anderson   +21 more
doaj   +1 more source

Daratumumab-induced transient myopic shift

American Journal of Ophthalmology Case Reports, 2019
Purpose: To describe an unprecedented case of transient myopic shift induced by a chemotherapeutic agent, daratumumab. Observations: A 43-year-old emmetropic female with multiple myeloma experienced sudden onset of myopic shift during her first ...
Maria A. Mavrommatis, Hoon Jung, Ajai Chari, Bart Barlogie, James G. Chelnis   +4 more
doaj   +1 more source

Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma

Journal for ImmunoTherapy of Cancer, 2021
Background The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL) was highlighted when its off-label usage produced sustained remission in a patient with highly refractory disease.
Jennifer Yang, Anand D Jeyasekharan, Joanne Lee, Wee Joo Chng, Tae-Hoon Chung, Nurulhuda Mustafa, Adina Huey Fang Nee, Jing Yuan Chooi, Sabrina Hui Min Toh, Viknesvaran Selvarajan, Shuangyi Fan, Siok Bian Ng, Michelle Poon, Esther Chan, Yen Lin Chee, Longen Zhou   +15 more
doaj   +1 more source

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review

American Journal of Hematology, EarlyView.
ABSTRACT Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options.
Ioannis Ntanasis‐Stathopoulos, Sotirios Manganas, Charalampos Filippatos, Konstantinos Karamouzis, Maria Gavriatopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios‐Athanasios Dimopoulos   +7 more
wiley   +1 more source

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion

Asia-Pacific Journal of Oncology Nursing, 2018
Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-existing medical conditions. They have often had multiple lines of therapy and as such experience disease-related effects alongside associated treatment ...
Tracy King, Jacqueline Jagger, Jodie Wood, Carmel Woodrow, Alicia Snowden, Sally Haines, Christina Crosbie, Kristen Houdyk   +7 more
doaj   +1 more source

Lifelong Evolution of Autoreactive Plasma Cell Numbers, Affinity, and Anatomic Location in Arthritic K/BxN Mice

Arthritis &Rheumatology, EarlyView.
Objective The spontaneous K/BxN mouse model of rheumatoid arthritis has been used extensively to study chronic inflammation, contribution of immune cells, and the primordial role of autoreactive antibodies in disease initiation and severity. Only the ubiquitous enzyme glucose‐6‐phosphate isomerase (GPI) is the target of IgG autoantibodies secreted by ...
Thibault Vanhoucke, Carlos Castrillon, Odile Richard‐Le Goff, Angga Perima, Matteo Broketa, Andrew D. Griffiths, Patrick England, François Huetz, Pierre Bruhns   +8 more
wiley   +1 more source

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

Cells, 2020
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line ...
Torben Plesner, Niels W. C. J. van de Donk, Paul G. Richardson   +2 more
doaj   +1 more source

Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials

Scientific Reports, 2021
Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone anti-myeloma treatments. Systematic search was performed up to August 2021 to identify randomised controlled trials
Szabolcs Kiss, Noémi Gede, Péter Hegyi, Bettina Nagy, Rita Deák, Fanni Dembrovszky, Stefania Bunduc, Bálint Erőss, Tamás Leiner, Zsolt Szakács, Hussain Alizadeh   +10 more
doaj   +1 more source

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland [PDF]

, 2015
The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss
Bargetzi, M., Betticher, D.C., Duchosal, M.A., Heim, D., Hess, U., Ketterer, N., Lerch, E., Matthes, T., Mey, U., Pabst, T., Renner, C., Samaras, P., Taverna, C., Zander, T.   +13 more
core   +4 more sources

Affinity Peptides With pH Sensitivity for the Enrichment of CD38+ Cells

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The selective enrichment of cell populations based on surface markers is critical for the advancement of gene and cell therapies. Current antibody‐based cell isolation methods, such as fluorescence‐ and magnetic‐activated cell sorting (FACS and MACS), offer high specificity but are limited by scalability, cost, and potential adverse effects on
Gabrielle Rusch, Mickael Meyer, I. Mohamed Irfan, Carson Huber, Joseph Burclaff, Scott T. Magness, Stefano Menegatti, Michael Daniele   +7 more
wiley   +1 more source